J. Kenneth Charles Knowles
Direttore/Membro del Consiglio presso Caris Life Sciences, LLC
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Pekka Ilmari Simula | M | 50 |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.
MediSapiens Oy
MediSapiens Oy Packaged SoftwareTechnology Services MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland. | 11 anni |
Lu Alleruzzo | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 15 anni |
David D. Halbert | M | - |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | 16 anni |
Tomas Hode | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 15 anni |
Elliot Norry | M | 61 | 9 anni | |
Sami Kalevi Kilpinen | M | - |
MediSapiens Oy
MediSapiens Oy Packaged SoftwareTechnology Services MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland. | 15 anni |
Carl Erik Mathias Uhlén | M | 70 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 26 anni |
Hassan Sadeghi | M | - |
École Polytechnique Fédérale de Lausanne
| - |
David Spetzler | M | - |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | 15 anni |
Karin Nord | M | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 26 anni |
Joachim Feldwisch | M | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Kalle Ojala | M | - |
MediSapiens Oy
MediSapiens Oy Packaged SoftwareTechnology Services MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland. | - |
Olli-Pekka Kallioniemi | M | - |
MediSapiens Oy
MediSapiens Oy Packaged SoftwareTechnology Services MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland. | 15 anni |
Ritva Marketta Toivonen | M | 62 |
University of Helsinki
| 8 anni |
Bengt Westermark | M | 79 |
European Molecular Biology Organization
| - |
Robert Forbes Burns | M | 77 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Joseph Raker | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Siu Kit Lam | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Henrik Edgren | M | - |
MediSapiens Oy
MediSapiens Oy Packaged SoftwareTechnology Services MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland. | - |
Hermona Soreq | M | - |
European Molecular Biology Organization
| - |
Dirk Heinz | M | - |
European Molecular Biology Organization
| 15 anni |
Marko Kuisma | M | - |
MediSapiens Oy
MediSapiens Oy Packaged SoftwareTechnology Services MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland. | - |
Paul Schulze Lefert | M | - |
European Molecular Biology Organization
| - |
Brian Lamon | M | - |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | - |
Carl-Hendrik Heldin | M | 72 |
European Molecular Biology Organization
| 8 anni |
Michael Owen | M | 73 |
European Molecular Biology Organization
| - |
Theo Lasser | M | - |
École Polytechnique Fédérale de Lausanne
| - |
Magnus Jaderberg | M | - |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | - |
Danny Phillips | M | - |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | - |
Petri Mika Tapani Parvinen | M | 47 |
University of Helsinki
| 10 anni |
Olivier Verscheure | M | 52 |
École Polytechnique Fédérale de Lausanne
| 6 anni |
Eva Galanis | F | - |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | - |
Camilla Soenderby | F | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Benoît Deveaud-Plédran | M | 53 |
École Polytechnique Fédérale de Lausanne
| - |
Raphael Roettgen | M | 51 |
École Polytechnique Fédérale de Lausanne
| - |
Hong Wu | M | 66 |
European Molecular Biology Organization
| 8 anni |
Juli P. Miller | M | - | 8 anni | |
Kirsti Lonka | M | 63 |
University of Helsinki
| 19 anni |
Karen Vousden | M | 66 |
European Molecular Biology Organization
| - |
Luca Gianni | M | - |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | - |
Daniel Chuard | M | - |
École Polytechnique Fédérale de Lausanne
| - |
Lily Kong | F | - |
Agency for Science, Technology & Research
Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | 7 anni |
Alan Ashworth | M | 63 |
European Molecular Biology Organization
| - |
Antonio Lanzavecchia | M | 73 |
European Molecular Biology Organization
| - |
Chen Wei | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Isabelle Romy | M | 59 |
École Polytechnique Fédérale de Lausanne
| 28 anni |
Laurent Vulliet | M | 66 |
École Polytechnique Fédérale de Lausanne
| 30 anni |
Fulvio Mavilio | M | - |
European Molecular Biology Organization
| - |
Robert Nordquist | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Petri Tapani Peltonen | M | 63 |
University of Helsinki
| - |
Damir Filipovic | M | 54 |
École Polytechnique Fédérale de Lausanne
| - |
Jeffrey A. Hubbell | M | - |
École Polytechnique Fédérale de Lausanne
| - |
Stig Anders Lindberg | M | 52 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Robert Kamen | M | 79 |
European Molecular Biology Organization
| 48 anni |
Olivier Steimer | M | 68 |
École Polytechnique Fédérale de Lausanne
| - |
Daniel L. Farkas | M | 70 |
European Molecular Biology Organization
| - |
Edward N. Brody | M | - |
European Molecular Biology Organization
| - |
Johan Auwerx | M | - |
École Polytechnique Fédérale de Lausanne
| 16 anni |
Erkki Ruoslahti | M | 84 |
European Molecular Biology Organization
| - |
Patrick Baeuerle | M | 66 |
European Molecular Biology Organization
| - |
Joseph P. Schlessinger | M | 79 |
European Molecular Biology Organization
| - |
Ruth Arnon | M | 90 |
European Molecular Biology Organization
| - |
Hans Lennart Rudolf Wigzell | M | 86 |
European Molecular Biology Organization
| - |
Jarmo Heiniö | M | 76 |
University of Helsinki
| 22 anni |
Peter M. Castleman | M | 67 |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | - |
Antti Tanskanen | M | 78 |
University of Helsinki
| 14 anni |
David Glover | M | - |
European Molecular Biology Organization
| - |
Jorma Jaakko Ollila | M | 73 |
University of Helsinki
| 15 anni |
George Poste | M | 79 |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | 15 anni |
David Smoller | M | 60 |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Laurie Johansen | F | - |
Caris Life Sciences, LLC
Caris Life Sciences, LLC Medical/Nursing ServicesHealth Services Caris Life Sciences Ltd. provides diagnostics and anatomic pathology services. The firm develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX. | 19 anni |
Bart F. Norré | M | - |
École Polytechnique Fédérale de Lausanne
| 21 anni |
Raymond Kaempfer | M | - |
European Molecular Biology Organization
| - |
David Bejker | M | 49 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 6 anni |
Gunvor Edith Maria Kronman | F | 61 |
University of Helsinki
| - |
Jose F. Suarez | M | 54 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Stephen Philip Jackson | M | - |
European Molecular Biology Organization
| 27 anni |
Bernard Gobert | M | - |
École Polytechnique Fédérale de Lausanne
| - |
Jukka Manner | M | 52 |
University of Helsinki
| 26 anni |
Mikko Salaspuro | M | 85 |
University of Helsinki
| - |
Tapio Juhani Koivu | M | - |
University of Helsinki
| - |
Yrjö Erik Kristian Wichmann | M | - |
University of Helsinki
| - |
Anders Martin-Löf | M | 53 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 3 anni |
Yigong Shi | M | 57 |
European Molecular Biology Organization
| - |
Claude Nicollier | M | - |
École Polytechnique Fédérale de Lausanne
| - |
Luke O'Neill | M | 60 |
European Molecular Biology Organization
| 19 anni |
Ashok Venkitaraman | M | - |
European Molecular Biology Organization
| - |
Spyridon Artavanis-Tsakonas | M | 77 |
European Molecular Biology Organization
| - |
Laurence Harris Pearl | M | - |
European Molecular Biology Organization
| - |
Peter Ratcliffe | M | 69 |
European Molecular Biology Organization
| - |
Patrick Volkert Vink | M | 60 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | - |
Susanna Miekk-oja | F | 74 |
University of Helsinki
| - |
Marja-Liisa Niinikosk | M | 56 |
University of Helsinki
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Ian Clark | M | 62 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 13 anni |
Louis Lavigne | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 23 anni |
Antti Vuolanto | M | - |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 6 anni |
Henri Juhani Huttunen | M | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 6 anni |
Robert A. Swanson | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 23 anni |
Michael Varney | M | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 15 anni |
Ari-Pekka Laitsaari | M | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Finlandia | 28 | 28.00% |
Germania | 28 | 28.00% |
Stati Uniti | 18 | 18.00% |
Svizzera | 15 | 15.00% |
Svezia | 9 | 9.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- J. Kenneth Charles Knowles
- Contatti personali